Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Down 39.2% in February

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the recipient of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 955,300 shares, a decline of 39.2% from the February 13th total of 1,570,000 shares. Based on an average daily trading volume, of 5,260,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 3.7% of the shares of the company are sold short.

Virpax Pharmaceuticals Stock Performance

NASDAQ:VRPX opened at $0.17 on Friday. Virpax Pharmaceuticals has a 12-month low of $0.16 and a 12-month high of $4.83. The stock’s 50 day moving average price is $0.28 and its two-hundred day moving average price is $0.48.

Institutional Investors Weigh In On Virpax Pharmaceuticals

An institutional investor recently bought a new position in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC bought a new position in shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned about 1.17% of Virpax Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 32.23% of the company’s stock.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.